Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01465386 · ClinicalTrials.gov registry record · Phase 2
Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission
A Phase 2 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01465386 is a Phase 2 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 6 participants.
The verdict
NCT01465386, a Phase 2 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This phase II trial studies how well bortezomib works in treating patients with high-risk acute myeloid leukemia (AML) in remission. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth
Interventions
- DRUG bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-03-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01465386
The ClinicalTrials.gov registry entry for NCT01465386 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bortezomib is the first listed.
NCT01465386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01465386 about?
NCT01465386 is a clinical study titled "Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission". This phase II trial studies how well bortezomib works in treating patients with high-risk acute myeloid leukemia (AML) in remission. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth
What is the current status of trial NCT01465386?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2011-11. Estimated completion is 2015-03-02.
What interventions are being tested in trial NCT01465386?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT01465386?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.